Briony L Duarte Romero

Ms. Briony L Duarte Romero

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Ophthalmology
Verified
Journal Article
Closed access
SRSabbir T. Rahman
Sabbir T. Rahman
MWMary Waterhouse
Mary Waterhouse
BRBriony L Duarte Romero
Briony L Duarte Romero
CBCatherine Baxter
Catherine Baxter
DEDallas English
Dallas English
RNRachel Neale
Rachel Neale

10 September 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
VTVu Tran
Vu Tran
BRBriony L Duarte Romero
Briony L Duarte Romero
HAHayley Andersen
Hayley Andersen
MCMichael Clarke
Michael Clarke
Louisa GordonLouisa Gordon
Louisa Gordon
RNRachel Neale
Rachel Neale
Background: Sunscreen reduces vitamin D production in experimental studies. It is uncertain whether this translates to real-world settings. Objectives: To determine if routinely applying high sun protection factor (SPF) sunscreen for a year reduces serum 25-hydroxyvitamin D [25(OH)D] concentration. Methods: We conducted a population-based open-label randomized controlled trial in Australian participants aged 18–70 years who were not routinely using sunscreen or taking vitamin D supplements. Participants were randomized (1 : 1) using stratified, computer-generated permuted block randomization to routine application of SPF 50+ sunscreen on days the ultraviolet (UV) index was forecast to reach ≥ 3 (intervention) or discretionary sunscreen use (control), for approximately 1 year. We measured 25(OH)D concentration at baseline (winter/spring 2022) and at the end of summer and winter 2023; participants with no postbaseline concentrations (n = 11) were excluded from analyses. The primary outcome was change in 25(OH)D concentration from baseline. Vitamin D deficiency [25(OH)D concentration < 50 nmol L–1] in the final sample was an exploratory outcome. We analysed data using mixed-effects models and Poisson regression. We stratified our analysis by baseline 25(OH)D concentration, residential UV radiation (UVR) zone, skin exposure (derived from time outdoors and clothing use) and personal UVR exposure (derived by combining UVR zone and skin exposure). Sample and data analysis were performed blind to randomization group. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621001752853). Results: Between 30 June and 29 November 2022, we randomized 639 participants (intervention, n = 319; control, n = 320). In total, 628 participants were analysed [intervention, n = 312; control, n = 316; median age 52 years (interquartile range 40–64)]. Altogether, 415 (66.1%) identified as female, 210 (33.4%) as male and 3 (0.5%) used another term. Mean (SD) baseline 25(OH)D concentration was balanced [intervention 63.5 (21.9) nmol L–1; control 62.1 (22.8) nmol L–1]. Adjusted mean differences from baseline were 1.6 nmol L–1 (intervention) and 6.8 nmol L–1 (control) [between-group treatment effect –5.2 nmol L–1, 95% confidence interval (CI) –7.2 to –3.2]. Treatment effects were consistent across almost all subgroups. Vitamin D deficiency (final sample) was higher in the intervention (n = 139/304; 45.7%) than in the control group (n = 115/312; 36.9%) (prevalence ratio 1.33, 95% CI 1.14–1.55). Conclusions: Routinely applying high SPF sunscreen results in lower 25(OH)D concentrations than would be seen with discretionary sunscreen use. Regular sunscreen users may need vitamin D supplementation.

22 January 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
BRBriony L Duarte Romero
Briony L Duarte Romero
BABruce Konrad Armstrong
Bruce Konrad Armstrong
CBCatherine Baxter
Catherine Baxter
DEDallas English
Dallas English
Peter  EbelingPeter Ebeling
Peter Ebeling
MWMary Waterhouse
Mary Waterhouse
Background/Objectives: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. Methods: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D3, conducted in Australians aged 60–84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian Pharmaceutical Benefits Scheme database. Follow-up began 6 months after randomization; we excluded participants without linked data, and those who were prevalent cases or who died prior to start of follow-up. Flexible parametric survival models were used to estimate the effect of vitamin D supplementation on each outcome. Results: We included 10,964 participants (vitamin D, n = 5456 [49.8%]; placebo, n = 5508 [50.2%]) in the analysis of hypertension, 12,126 participants (vitamin D, n = 6038 [49.8%]; placebo, n = 6088 [50.2%]) in the analysis of hypercholesterolemia, and 17,846 (vitamin D, n = 8931 [50.0%]; placebo, n = 8915 [50.0%]) in the analysis of T2D. Over a median follow-up of 4.6 years, 2672 (24.4%), 2554 (21.1%), and 779 (4.4%) participants developed hypertension, hypercholesterolemia, and T2D, respectively. Vitamin D supplementation had no material effect on the incidence of any of hypertension (HR 1.00; 95% CI 0.93 to 1.08), hypercholesterolemia (HR 1.05; 95% CI 0.97 to 1.13), or T2D (HR 0.97; 95% CI 0.84 to 1.12). Conclusions: Monthly supplements of vitamin D did not alter the incidence of any of the three conditions in older, largely vitamin D-replete Australians.